Midatech Pharma US Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY14 | FY13 | FY12 | FY11 | FY10 | |
|---|---|---|---|---|---|
| Revenue | $1.9M | $419,322 | $53,629 | — | — |
| Operating income | −$9.4M | −$10.5M | −$9.6M | −$6.8M | −$6.5M |
| Net income | −$9.0M | −$10.0M | −$7.3M | −$6.2M | −$5.7M |
| Total assets | $17.8M | $8.0M | $11.7M | $1.9M | $6.4M |
| Total liabilities | $3.8M | $2.4M | $2.7M | $893,194 | $1.2M |
| Equity | $13.9M | $6.6M | $9.6M | $1.2M | $5.1M |
| EPS (diluted) | — | — | — | — | — |
| Shares out. | 31.1M | 25.0M | 7.0M | 5.6M | 4.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2014- Operating margin
- −498.3%
- Net margin
- −477.1%
- Return on equity
- −64.7%
- Return on assets
- −50.7%
- Return on capital (ROCE)
- −67.1%
- Liabilities / assets
- 21.6%
- Debt / equity
- 0.28×
- Book value / share
- $0.45
- Revenue growth (YoY)
- 349.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2014- Altman Z″ (distress)
- -8.16distress
- Accruals / assets
- −5.7%clean
- Beneish M-Score
- 0.84elevated
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsDec 4, 2015
- Shareholder vote · Other material eventDec 2, 2015
- Delisting / listing-standard noticeNov 18, 2015
- Results of operationsNov 2, 2015
- Results of operationsAug 12, 2015
- Entered a material agreement · Other material eventJun 4, 2015
- Delisting / listing-standard noticeMay 19, 2015
- Results of operationsMay 13, 2015
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.